| Hospital Safety During the COVID-19 Pandemic: A Closer Look at Nursing-Sensitive Quality Indicators | 03/24/2025 | |
| The Aryl Hydrocarbon Receptor and Lupus: Diagnostic and Therapeutic Advancements | 03/26/2025 | |
| Managing Lupus: Tailored Strategies for Flares and Fatigue Relief | 03/26/2025 | |
| Rare Kidney Disease: A Parent and Caregiver’s Perspective | 02/17/2025 | |
| The Diagnostic Journey of IgA Nephropathy: Identifying Key Obstacles | 03/26/2025 | |
| Deciphering IgA Nephropathy: Insights into the Diagnostic Process | 03/19/2025 | |
| Advances in IgAN: New Frontiers in Biomarkers and Treatment | 03/01/2025 | |
| Diagnosing IgA Nephropathy: The Role of Immunofluorescence and Immunohistochemistry | 03/22/2025 | |
| Enhancing Outcomes in Relapsed/Refractory B-ALL with CAR T-Cell Therapy | 03/25/2025 | |
| Assessing the AMA MAPTM Hypertension Program’s Impact at Rush University Medical Center | 03/22/2025 | |
| Examining a Therapeutic Modality for 2L+ mNSCLC | 03/26/2025 | |
| Improving CKD Patient Outcomes with SGLT2 Inhibitors | 11/17/2024 | |
| Clinical Insights into Higher-Risk MDS: Treatment Goals and Strategies | 03/25/2025 | |
| Insights into the IgAN Patient Journey: From Diagnosis to Treatment | 03/02/2024 | |
| Unpacking Myelofibrosis: Pathogenesis and Management Goals | 03/24/2025 | |
